Stem Cell Therapy Comprehensive Study by Type (Autologous, Allogeneic), Application (CNS, CVS, GIT, Wounds and Injuries, Musculoskeletal, Eye, Immune System, Others), Cell Source (Adipose tissue, Bone Marrow, Embro/Cord Blood Derived, IPSCs (Induced Pluripotent Stem Cell)), End user (Therapeutic Companies, Cell and Tissue Banks, Tools and Reagents Companies, Service Companies, Hospitals) Players and Region - Global Market Outlook to 2026

Report Objectives / Segmentation Covered

• Autologous
• Allogeneic

• CNS
• CVS
• GIT
• Wounds and Injuries
• Musculoskeletal
• Eye
• Immune System
• Others

• Adipose tissue
• Bone Marrow
• Embro/Cord Blood Derived
• IPSCs (Induced Pluripotent Stem Cell)

• Therapeutic Companies
• Cell and Tissue Banks
• Tools and Reagents Companies
• Service Companies
• Hospitals

• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • Italy
  • United Kingdom
  • Netherlands
  • Rest of Europe
• MEA
  • Middle East
  • Africa
• North America
  • United States
  • Canada
  • Mexico

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Dynamics
  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Significant rise in the number of clinical application of stem cells and advantages of stem cell therapies
    • 3.2.2. Rapid infrastructure development and increasing disposable income of the consumers
    • 3.2.3. Increasing awareness among people about therapeutic potency of stem cells
    • 3.2.4. Technology advancement in healthcare curing life threatening diseases and giving promising results.
  • 3.3. Market Challenges
    • 3.3.1. Complexity related with preservation of stem cells
    • 3.3.2. Rising cost of the clinical trials conducted for stem cell therapy by the researchers.
  • 3.4. Market Trends
    • 3.4.1. Increasing cost of stem cell therapy procedure
    • 3.4.2. Technological advancement in healthcare and identification of new stem cell line.
• 4. Market Factor Analysis
  • 4.1. Porters Five Forces
  • 4.2. Supply/Value Chain
  • 4.3. PESTEL analysis
  • 4.4. Market Entropy
  • 4.5. Patent/Trademark Analysis
• 5. Global Stem Cell Therapy, by Type, Application, Cell Source, End user and Region (value) (2015-2020)
  • 5.1. Introduction
  • 5.2. Global Stem Cell Therapy (Value)
    • 5.2.1. Global Stem Cell Therapy by: Type (Value)
      • 5.2.1.1. Autologous
      • 5.2.1.2. Allogeneic
    • 5.2.2. Global Stem Cell Therapy by: Application (Value)
      • 5.2.2.1. CNS
      • 5.2.2.2. CVS
      • 5.2.2.3. GIT
      • 5.2.2.4. Wounds and Injuries
      • 5.2.2.5. Musculoskeletal
      • 5.2.2.6. Eye
      • 5.2.2.7. Immune System
      • 5.2.2.8. Others
    • 5.2.3. Global Stem Cell Therapy by: Cell Source (Value)
      • 5.2.3.1. Adipose tissue
      • 5.2.3.2. Bone Marrow
      • 5.2.3.3. Embro/Cord Blood Derived
      • 5.2.3.4. IPSCs (Induced Pluripotent Stem Cell)
    • 5.2.4. Global Stem Cell Therapy by: End user (Value)
      • 5.2.4.1. Therapeutic Companies
      • 5.2.4.2. Cell and Tissue Banks
      • 5.2.4.3. Tools and Reagents Companies
      • 5.2.4.4. Service Companies
      • 5.2.4.5. Hospitals
    • 5.2.5. Global Stem Cell Therapy Region
      • 5.2.5.1. South America
        • 5.2.5.1.1. Brazil
        • 5.2.5.1.2. Argentina
        • 5.2.5.1.3. Rest of South America
      • 5.2.5.2. Asia Pacific
        • 5.2.5.2.1. China
        • 5.2.5.2.2. Japan
        • 5.2.5.2.3. India
        • 5.2.5.2.4. South Korea
        • 5.2.5.2.5. Taiwan
        • 5.2.5.2.6. Australia
        • 5.2.5.2.7. Rest of Asia-Pacific
      • 5.2.5.3. Europe
        • 5.2.5.3.1. Germany
        • 5.2.5.3.2. France
        • 5.2.5.3.3. Italy
        • 5.2.5.3.4. United Kingdom
        • 5.2.5.3.5. Netherlands
        • 5.2.5.3.6. Rest of Europe
      • 5.2.5.4. MEA
        • 5.2.5.4.1. Middle East
        • 5.2.5.4.2. Africa
      • 5.2.5.5. North America
        • 5.2.5.5.1. United States
        • 5.2.5.5.2. Canada
        • 5.2.5.5.3. Mexico
• 6. Stem Cell Therapy: Manufacturers/Players Analysis
  • 6.1. Competitive Landscape
    • 6.1.1. Market Share Analysis
      • 6.1.1.1. Top 3
      • 6.1.1.2. Top 5
  • 6.2. Peer Group Analysis (2020)
  • 6.3. BCG Matrix
  • 6.4. Company Profile
    • 6.4.1. Cellular Dynamics International, Inc. (United States)
      • 6.4.1.1. Business Overview
      • 6.4.1.2. Products/Services Offerings
      • 6.4.1.3. Financial Analysis
      • 6.4.1.4. SWOT Analysis
    • 6.4.2. Osiris Therapeutics (United States)
      • 6.4.2.1. Business Overview
      • 6.4.2.2. Products/Services Offerings
      • 6.4.2.3. Financial Analysis
      • 6.4.2.4. SWOT Analysis
    • 6.4.3. Vcanbio Cell & Gene Corp. Ltd. (United States)
      • 6.4.3.1. Business Overview
      • 6.4.3.2. Products/Services Offerings
      • 6.4.3.3. Financial Analysis
      • 6.4.3.4. SWOT Analysis
    • 6.4.4. Gamida-Cell Ltd. (Israel)
      • 6.4.4.1. Business Overview
      • 6.4.4.2. Products/Services Offerings
      • 6.4.4.3. Financial Analysis
      • 6.4.4.4. SWOT Analysis
    • 6.4.5. Golden Meditech Holdings Limited (Hong Kong)
      • 6.4.5.1. Business Overview
      • 6.4.5.2. Products/Services Offerings
      • 6.4.5.3. Financial Analysis
      • 6.4.5.4. SWOT Analysis
    • 6.4.6. Celgene Corp. (United States)
      • 6.4.6.1. Business Overview
      • 6.4.6.2. Products/Services Offerings
      • 6.4.6.3. Financial Analysis
      • 6.4.6.4. SWOT Analysis
    • 6.4.7. Guanhao Biotech Co. (China)
      • 6.4.7.1. Business Overview
      • 6.4.7.2. Products/Services Offerings
      • 6.4.7.3. Financial Analysis
      • 6.4.7.4. SWOT Analysis
    • 6.4.8. Mesoblast Ltd. (Australia)
      • 6.4.8.1. Business Overview
      • 6.4.8.2. Products/Services Offerings
      • 6.4.8.3. Financial Analysis
      • 6.4.8.4. SWOT Analysis
    • 6.4.9. Vericel Corp. (United States)
      • 6.4.9.1. Business Overview
      • 6.4.9.2. Products/Services Offerings
      • 6.4.9.3. Financial Analysis
      • 6.4.9.4. SWOT Analysis
    • 6.4.10. Stemcell Technologies Inc. (Canada)
      • 6.4.10.1. Business Overview
      • 6.4.10.2. Products/Services Offerings
      • 6.4.10.3. Financial Analysis
      • 6.4.10.4. SWOT Analysis
    • 6.4.11. Beike Biotechnology co., Ltd. (China)
      • 6.4.11.1. Business Overview
      • 6.4.11.2. Products/Services Offerings
      • 6.4.11.3. Financial Analysis
      • 6.4.11.4. SWOT Analysis
    • 6.4.12. Cytori Therapeutics, Inc. (United States)
      • 6.4.12.1. Business Overview
      • 6.4.12.2. Products/Services Offerings
      • 6.4.12.3. Financial Analysis
      • 6.4.12.4. SWOT Analysis
    • 6.4.13. Bioheart Inc. (United States)
      • 6.4.13.1. Business Overview
      • 6.4.13.2. Products/Services Offerings
      • 6.4.13.3. Financial Analysis
      • 6.4.13.4. SWOT Analysis
    • 6.4.14. Universal Cells, Inc. (Japan)
      • 6.4.14.1. Business Overview
      • 6.4.14.2. Products/Services Offerings
      • 6.4.14.3. Financial Analysis
      • 6.4.14.4. SWOT Analysis
    • 6.4.15. Athersys, Inc. (United States)
      • 6.4.15.1. Business Overview
      • 6.4.15.2. Products/Services Offerings
      • 6.4.15.3. Financial Analysis
      • 6.4.15.4. SWOT Analysis
    • 6.4.16. Geron Corp. (United States)
      • 6.4.16.1. Business Overview
      • 6.4.16.2. Products/Services Offerings
      • 6.4.16.3. Financial Analysis
      • 6.4.16.4. SWOT Analysis
    • 6.4.17. Pluristem Therapeutics (Israel)
      • 6.4.17.1. Business Overview
      • 6.4.17.2. Products/Services Offerings
      • 6.4.17.3. Financial Analysis
      • 6.4.17.4. SWOT Analysis
    • 6.4.18. Fibrocell Science (United States)
      • 6.4.18.1. Business Overview
      • 6.4.18.2. Products/Services Offerings
      • 6.4.18.3. Financial Analysis
      • 6.4.18.4. SWOT Analysis
    • 6.4.19. Astellas US Holding, Inc. (United States)
      • 6.4.19.1. Business Overview
      • 6.4.19.2. Products/Services Offerings
      • 6.4.19.3. Financial Analysis
      • 6.4.19.4. SWOT Analysis
    • 6.4.20. MEDIPOST Co., Ltd. (South Korea)
      • 6.4.20.1. Business Overview
      • 6.4.20.2. Products/Services Offerings
      • 6.4.20.3. Financial Analysis
      • 6.4.20.4. SWOT Analysis
    • 6.4.21. Anterogen Co., Ltd. (South Korea)
      • 6.4.21.1. Business Overview
      • 6.4.21.2. Products/Services Offerings
      • 6.4.21.3. Financial Analysis
      • 6.4.21.4. SWOT Analysis
    • 6.4.22. Pharmicell Co., Ltd. (South Korea)
      • 6.4.22.1. Business Overview
      • 6.4.22.2. Products/Services Offerings
      • 6.4.22.3. Financial Analysis
      • 6.4.22.4. SWOT Analysis
    • 6.4.23. Holostem Terapie Avanzate S.r.l (Italy)
      • 6.4.23.1. Business Overview
      • 6.4.23.2. Products/Services Offerings
      • 6.4.23.3. Financial Analysis
      • 6.4.23.4. SWOT Analysis
    • 6.4.24. JCR Pharmaceuticals Co., Ltd. (Japan)
      • 6.4.24.1. Business Overview
      • 6.4.24.2. Products/Services Offerings
      • 6.4.24.3. Financial Analysis
      • 6.4.24.4. SWOT Analysis
    • 6.4.25. NuVasive, Inc. (United States)
      • 6.4.25.1. Business Overview
      • 6.4.25.2. Products/Services Offerings
      • 6.4.25.3. Financial Analysis
      • 6.4.25.4. SWOT Analysis
    • 6.4.26. RTI Surgical, Inc. (United States)
      • 6.4.26.1. Business Overview
      • 6.4.26.2. Products/Services Offerings
      • 6.4.26.3. Financial Analysis
      • 6.4.26.4. SWOT Analysis
    • 6.4.27. AlloSource (United States)
      • 6.4.27.1. Business Overview
      • 6.4.27.2. Products/Services Offerings
      • 6.4.27.3. Financial Analysis
      • 6.4.27.4. SWOT Analysis
    • 6.4.28. Novartis International AG (Switzerland)
      • 6.4.28.1. Business Overview
      • 6.4.28.2. Products/Services Offerings
      • 6.4.28.3. Financial Analysis
      • 6.4.28.4. SWOT Analysis
    • 6.4.29. Gilead Sciences (United States)
      • 6.4.29.1. Business Overview
      • 6.4.29.2. Products/Services Offerings
      • 6.4.29.3. Financial Analysis
      • 6.4.29.4. SWOT Analysis
• 7. Global Stem Cell Therapy Sale, by Type, Application, Cell Source, End user and Region (value) (2021-2026)
  • 7.1. Introduction
  • 7.2. Global Stem Cell Therapy (Value)
    • 7.2.1. Global Stem Cell Therapy by: Type (Value)
      • 7.2.1.1. Autologous
      • 7.2.1.2. Allogeneic
    • 7.2.2. Global Stem Cell Therapy by: Application (Value)
      • 7.2.2.1. CNS
      • 7.2.2.2. CVS
      • 7.2.2.3. GIT
      • 7.2.2.4. Wounds and Injuries
      • 7.2.2.5. Musculoskeletal
      • 7.2.2.6. Eye
      • 7.2.2.7. Immune System
      • 7.2.2.8. Others
    • 7.2.3. Global Stem Cell Therapy by: Cell Source (Value)
      • 7.2.3.1. Adipose tissue
      • 7.2.3.2. Bone Marrow
      • 7.2.3.3. Embro/Cord Blood Derived
      • 7.2.3.4. IPSCs (Induced Pluripotent Stem Cell)
    • 7.2.4. Global Stem Cell Therapy by: End user (Value)
      • 7.2.4.1. Therapeutic Companies
      • 7.2.4.2. Cell and Tissue Banks
      • 7.2.4.3. Tools and Reagents Companies
      • 7.2.4.4. Service Companies
      • 7.2.4.5. Hospitals
    • 7.2.5. Global Stem Cell Therapy Region
      • 7.2.5.1. South America
        • 7.2.5.1.1. Brazil
        • 7.2.5.1.2. Argentina
        • 7.2.5.1.3. Rest of South America
      • 7.2.5.2. Asia Pacific
        • 7.2.5.2.1. China
        • 7.2.5.2.2. Japan
        • 7.2.5.2.3. India
        • 7.2.5.2.4. South Korea
        • 7.2.5.2.5. Taiwan
        • 7.2.5.2.6. Australia
        • 7.2.5.2.7. Rest of Asia-Pacific
      • 7.2.5.3. Europe
        • 7.2.5.3.1. Germany
        • 7.2.5.3.2. France
        • 7.2.5.3.3. Italy
        • 7.2.5.3.4. United Kingdom
        • 7.2.5.3.5. Netherlands
        • 7.2.5.3.6. Rest of Europe
      • 7.2.5.4. MEA
        • 7.2.5.4.1. Middle East
        • 7.2.5.4.2. Africa
      • 7.2.5.5. North America
        • 7.2.5.5.1. United States
        • 7.2.5.5.2. Canada
        • 7.2.5.5.3. Mexico
• 8. Appendix
  • 8.1. Acronyms
• 9. Methodology and Data Source
  • 9.1. Methodology/Research Approach
    • 9.1.1. Research Programs/Design
    • 9.1.2. Market Size Estimation
    • 9.1.3. Market Breakdown and Data Triangulation
  • 9.2. Data Source
    • 9.2.1. Secondary Sources
    • 9.2.2. Primary Sources
  • 9.3. Disclaimer

• Table 1. Stem Cell Therapy: by Type(USD Million)
• Table 2. Stem Cell Therapy Autologous , by Region USD Million (2015-2020)
• Table 3. Stem Cell Therapy Allogeneic , by Region USD Million (2015-2020)
• Table 4. Stem Cell Therapy: by Application(USD Million)
• Table 5. Stem Cell Therapy CNS , by Region USD Million (2015-2020)
• Table 6. Stem Cell Therapy CVS , by Region USD Million (2015-2020)
• Table 7. Stem Cell Therapy GIT , by Region USD Million (2015-2020)
• Table 8. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2015-2020)
• Table 9. Stem Cell Therapy Musculoskeletal , by Region USD Million (2015-2020)
• Table 10. Stem Cell Therapy Eye , by Region USD Million (2015-2020)
• Table 11. Stem Cell Therapy Immune System , by Region USD Million (2015-2020)
• Table 12. Stem Cell Therapy Others , by Region USD Million (2015-2020)
• Table 13. Stem Cell Therapy: by Cell Source(USD Million)
• Table 14. Stem Cell Therapy Adipose tissue , by Region USD Million (2015-2020)
• Table 15. Stem Cell Therapy Bone Marrow , by Region USD Million (2015-2020)
• Table 16. Stem Cell Therapy Embro/Cord Blood Derived , by Region USD Million (2015-2020)
• Table 17. Stem Cell Therapy IPSCs (Induced Pluripotent Stem Cell) , by Region USD Million (2015-2020)
• Table 18. Stem Cell Therapy: by End user(USD Million)
• Table 19. Stem Cell Therapy Therapeutic Companies , by Region USD Million (2015-2020)
• Table 20. Stem Cell Therapy Cell and Tissue Banks , by Region USD Million (2015-2020)
• Table 21. Stem Cell Therapy Tools and Reagents Companies , by Region USD Million (2015-2020)
• Table 22. Stem Cell Therapy Service Companies , by Region USD Million (2015-2020)
• Table 23. Stem Cell Therapy Hospitals , by Region USD Million (2015-2020)
• Table 24. South America Stem Cell Therapy, by Country USD Million (2015-2020)
• Table 25. South America Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 26. South America Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 27. South America Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 28. South America Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 29. Brazil Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 30. Brazil Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 31. Brazil Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 32. Brazil Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 33. Argentina Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 34. Argentina Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 35. Argentina Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 36. Argentina Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 37. Rest of South America Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 38. Rest of South America Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 39. Rest of South America Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 40. Rest of South America Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 41. Asia Pacific Stem Cell Therapy, by Country USD Million (2015-2020)
• Table 42. Asia Pacific Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 43. Asia Pacific Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 44. Asia Pacific Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 45. Asia Pacific Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 46. China Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 47. China Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 48. China Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 49. China Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 50. Japan Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 51. Japan Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 52. Japan Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 53. Japan Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 54. India Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 55. India Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 56. India Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 57. India Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 58. South Korea Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 59. South Korea Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 60. South Korea Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 61. South Korea Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 62. Taiwan Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 63. Taiwan Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 64. Taiwan Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 65. Taiwan Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 66. Australia Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 67. Australia Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 68. Australia Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 69. Australia Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 70. Rest of Asia-Pacific Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 71. Rest of Asia-Pacific Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 72. Rest of Asia-Pacific Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 73. Rest of Asia-Pacific Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 74. Europe Stem Cell Therapy, by Country USD Million (2015-2020)
• Table 75. Europe Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 76. Europe Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 77. Europe Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 78. Europe Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 79. Germany Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 80. Germany Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 81. Germany Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 82. Germany Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 83. France Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 84. France Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 85. France Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 86. France Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 87. Italy Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 88. Italy Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 89. Italy Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 90. Italy Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 91. United Kingdom Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 92. United Kingdom Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 93. United Kingdom Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 94. United Kingdom Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 95. Netherlands Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 96. Netherlands Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 97. Netherlands Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 98. Netherlands Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 99. Rest of Europe Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 100. Rest of Europe Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 101. Rest of Europe Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 102. Rest of Europe Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 103. MEA Stem Cell Therapy, by Country USD Million (2015-2020)
• Table 104. MEA Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 105. MEA Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 106. MEA Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 107. MEA Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 108. Middle East Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 109. Middle East Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 110. Middle East Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 111. Middle East Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 112. Africa Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 113. Africa Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 114. Africa Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 115. Africa Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 116. North America Stem Cell Therapy, by Country USD Million (2015-2020)
• Table 117. North America Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 118. North America Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 119. North America Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 120. North America Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 121. United States Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 122. United States Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 123. United States Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 124. United States Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 125. Canada Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 126. Canada Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 127. Canada Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 128. Canada Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 129. Mexico Stem Cell Therapy, by Type USD Million (2015-2020)
• Table 130. Mexico Stem Cell Therapy, by Application USD Million (2015-2020)
• Table 131. Mexico Stem Cell Therapy, by Cell Source USD Million (2015-2020)
• Table 132. Mexico Stem Cell Therapy, by End user USD Million (2015-2020)
• Table 133. Company Basic Information, Sales Area and Its Competitors
• Table 134. Company Basic Information, Sales Area and Its Competitors
• Table 135. Company Basic Information, Sales Area and Its Competitors
• Table 136. Company Basic Information, Sales Area and Its Competitors
• Table 137. Company Basic Information, Sales Area and Its Competitors
• Table 138. Company Basic Information, Sales Area and Its Competitors
• Table 139. Company Basic Information, Sales Area and Its Competitors
• Table 140. Company Basic Information, Sales Area and Its Competitors
• Table 141. Company Basic Information, Sales Area and Its Competitors
• Table 142. Company Basic Information, Sales Area and Its Competitors
• Table 143. Company Basic Information, Sales Area and Its Competitors
• Table 144. Company Basic Information, Sales Area and Its Competitors
• Table 145. Company Basic Information, Sales Area and Its Competitors
• Table 146. Company Basic Information, Sales Area and Its Competitors
• Table 147. Company Basic Information, Sales Area and Its Competitors
• Table 148. Company Basic Information, Sales Area and Its Competitors
• Table 149. Company Basic Information, Sales Area and Its Competitors
• Table 150. Company Basic Information, Sales Area and Its Competitors
• Table 151. Company Basic Information, Sales Area and Its Competitors
• Table 152. Company Basic Information, Sales Area and Its Competitors
• Table 153. Company Basic Information, Sales Area and Its Competitors
• Table 154. Company Basic Information, Sales Area and Its Competitors
• Table 155. Company Basic Information, Sales Area and Its Competitors
• Table 156. Company Basic Information, Sales Area and Its Competitors
• Table 157. Company Basic Information, Sales Area and Its Competitors
• Table 158. Company Basic Information, Sales Area and Its Competitors
• Table 159. Company Basic Information, Sales Area and Its Competitors
• Table 160. Company Basic Information, Sales Area and Its Competitors
• Table 161. Company Basic Information, Sales Area and Its Competitors
• Table 162. Stem Cell Therapy: by Type(USD Million)
• Table 163. Stem Cell Therapy Autologous , by Region USD Million (2021-2026)
• Table 164. Stem Cell Therapy Allogeneic , by Region USD Million (2021-2026)
• Table 165. Stem Cell Therapy: by Application(USD Million)
• Table 166. Stem Cell Therapy CNS , by Region USD Million (2021-2026)
• Table 167. Stem Cell Therapy CVS , by Region USD Million (2021-2026)
• Table 168. Stem Cell Therapy GIT , by Region USD Million (2021-2026)
• Table 169. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2021-2026)
• Table 170. Stem Cell Therapy Musculoskeletal , by Region USD Million (2021-2026)
• Table 171. Stem Cell Therapy Eye , by Region USD Million (2021-2026)
• Table 172. Stem Cell Therapy Immune System , by Region USD Million (2021-2026)
• Table 173. Stem Cell Therapy Others , by Region USD Million (2021-2026)
• Table 174. Stem Cell Therapy: by Cell Source(USD Million)
• Table 175. Stem Cell Therapy Adipose tissue , by Region USD Million (2021-2026)
• Table 176. Stem Cell Therapy Bone Marrow , by Region USD Million (2021-2026)
• Table 177. Stem Cell Therapy Embro/Cord Blood Derived , by Region USD Million (2021-2026)
• Table 178. Stem Cell Therapy IPSCs (Induced Pluripotent Stem Cell) , by Region USD Million (2021-2026)
• Table 179. Stem Cell Therapy: by End user(USD Million)
• Table 180. Stem Cell Therapy Therapeutic Companies , by Region USD Million (2021-2026)
• Table 181. Stem Cell Therapy Cell and Tissue Banks , by Region USD Million (2021-2026)
• Table 182. Stem Cell Therapy Tools and Reagents Companies , by Region USD Million (2021-2026)
• Table 183. Stem Cell Therapy Service Companies , by Region USD Million (2021-2026)
• Table 184. Stem Cell Therapy Hospitals , by Region USD Million (2021-2026)
• Table 185. South America Stem Cell Therapy, by Country USD Million (2021-2026)
• Table 186. South America Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 187. South America Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 188. South America Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 189. South America Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 190. Brazil Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 191. Brazil Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 192. Brazil Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 193. Brazil Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 194. Argentina Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 195. Argentina Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 196. Argentina Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 197. Argentina Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 198. Rest of South America Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 199. Rest of South America Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 200. Rest of South America Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 201. Rest of South America Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 202. Asia Pacific Stem Cell Therapy, by Country USD Million (2021-2026)
• Table 203. Asia Pacific Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 204. Asia Pacific Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 205. Asia Pacific Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 206. Asia Pacific Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 207. China Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 208. China Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 209. China Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 210. China Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 211. Japan Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 212. Japan Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 213. Japan Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 214. Japan Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 215. India Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 216. India Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 217. India Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 218. India Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 219. South Korea Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 220. South Korea Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 221. South Korea Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 222. South Korea Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 223. Taiwan Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 224. Taiwan Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 225. Taiwan Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 226. Taiwan Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 227. Australia Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 228. Australia Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 229. Australia Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 230. Australia Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 231. Rest of Asia-Pacific Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 232. Rest of Asia-Pacific Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 233. Rest of Asia-Pacific Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 234. Rest of Asia-Pacific Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 235. Europe Stem Cell Therapy, by Country USD Million (2021-2026)
• Table 236. Europe Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 237. Europe Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 238. Europe Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 239. Europe Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 240. Germany Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 241. Germany Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 242. Germany Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 243. Germany Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 244. France Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 245. France Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 246. France Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 247. France Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 248. Italy Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 249. Italy Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 250. Italy Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 251. Italy Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 252. United Kingdom Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 253. United Kingdom Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 254. United Kingdom Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 255. United Kingdom Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 256. Netherlands Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 257. Netherlands Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 258. Netherlands Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 259. Netherlands Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 260. Rest of Europe Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 261. Rest of Europe Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 262. Rest of Europe Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 263. Rest of Europe Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 264. MEA Stem Cell Therapy, by Country USD Million (2021-2026)
• Table 265. MEA Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 266. MEA Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 267. MEA Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 268. MEA Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 269. Middle East Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 270. Middle East Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 271. Middle East Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 272. Middle East Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 273. Africa Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 274. Africa Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 275. Africa Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 276. Africa Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 277. North America Stem Cell Therapy, by Country USD Million (2021-2026)
• Table 278. North America Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 279. North America Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 280. North America Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 281. North America Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 282. United States Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 283. United States Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 284. United States Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 285. United States Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 286. Canada Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 287. Canada Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 288. Canada Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 289. Canada Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 290. Mexico Stem Cell Therapy, by Type USD Million (2021-2026)
• Table 291. Mexico Stem Cell Therapy, by Application USD Million (2021-2026)
• Table 292. Mexico Stem Cell Therapy, by Cell Source USD Million (2021-2026)
• Table 293. Mexico Stem Cell Therapy, by End user USD Million (2021-2026)
• Table 294. Research Programs/Design for This Report
• Table 295. Key Data Information from Secondary Sources
• Table 296. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Stem Cell Therapy: by Type USD Million (2015-2020)
• Figure 5. Global Stem Cell Therapy: by Application USD Million (2015-2020)
• Figure 6. Global Stem Cell Therapy: by Cell Source USD Million (2015-2020)
• Figure 7. Global Stem Cell Therapy: by End user USD Million (2015-2020)
• Figure 8. South America Stem Cell Therapy Share (%), by Country
• Figure 9. Asia Pacific Stem Cell Therapy Share (%), by Country
• Figure 10. Europe Stem Cell Therapy Share (%), by Country
• Figure 11. MEA Stem Cell Therapy Share (%), by Country
• Figure 12. North America Stem Cell Therapy Share (%), by Country
• Figure 13. Global Stem Cell Therapy share by Players 2020 (%)
• Figure 14. Global Stem Cell Therapy share by Players (Top 3) 2020(%)
• Figure 15. Global Stem Cell Therapy share by Players (Top 5) 2020(%)
• Figure 16. BCG Matrix for key Companies
• Figure 17. Cellular Dynamics International, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 18. Cellular Dynamics International, Inc. (United States) Revenue: by Geography 2020
• Figure 19. Osiris Therapeutics (United States) Revenue, Net Income and Gross profit
• Figure 20. Osiris Therapeutics (United States) Revenue: by Geography 2020
• Figure 21. Vcanbio Cell & Gene Corp. Ltd. (United States) Revenue, Net Income and Gross profit
• Figure 22. Vcanbio Cell & Gene Corp. Ltd. (United States) Revenue: by Geography 2020
• Figure 23. Gamida-Cell Ltd. (Israel) Revenue, Net Income and Gross profit
• Figure 24. Gamida-Cell Ltd. (Israel) Revenue: by Geography 2020
• Figure 25. Golden Meditech Holdings Limited (Hong Kong) Revenue, Net Income and Gross profit
• Figure 26. Golden Meditech Holdings Limited (Hong Kong) Revenue: by Geography 2020
• Figure 27. Celgene Corp. (United States) Revenue, Net Income and Gross profit
• Figure 28. Celgene Corp. (United States) Revenue: by Geography 2020
• Figure 29. Guanhao Biotech Co. (China) Revenue, Net Income and Gross profit
• Figure 30. Guanhao Biotech Co. (China) Revenue: by Geography 2020
• Figure 31. Mesoblast Ltd. (Australia) Revenue, Net Income and Gross profit
• Figure 32. Mesoblast Ltd. (Australia) Revenue: by Geography 2020
• Figure 33. Vericel Corp. (United States) Revenue, Net Income and Gross profit
• Figure 34. Vericel Corp. (United States) Revenue: by Geography 2020
• Figure 35. Stemcell Technologies Inc. (Canada) Revenue, Net Income and Gross profit
• Figure 36. Stemcell Technologies Inc. (Canada) Revenue: by Geography 2020
• Figure 37. Beike Biotechnology co., Ltd. (China) Revenue, Net Income and Gross profit
• Figure 38. Beike Biotechnology co., Ltd. (China) Revenue: by Geography 2020
• Figure 39. Cytori Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 40. Cytori Therapeutics, Inc. (United States) Revenue: by Geography 2020
• Figure 41. Bioheart Inc. (United States) Revenue, Net Income and Gross profit
• Figure 42. Bioheart Inc. (United States) Revenue: by Geography 2020
• Figure 43. Universal Cells, Inc. (Japan) Revenue, Net Income and Gross profit
• Figure 44. Universal Cells, Inc. (Japan) Revenue: by Geography 2020
• Figure 45. Athersys, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 46. Athersys, Inc. (United States) Revenue: by Geography 2020
• Figure 47. Geron Corp. (United States) Revenue, Net Income and Gross profit
• Figure 48. Geron Corp. (United States) Revenue: by Geography 2020
• Figure 49. Pluristem Therapeutics (Israel) Revenue, Net Income and Gross profit
• Figure 50. Pluristem Therapeutics (Israel) Revenue: by Geography 2020
• Figure 51. Fibrocell Science (United States) Revenue, Net Income and Gross profit
• Figure 52. Fibrocell Science (United States) Revenue: by Geography 2020
• Figure 53. Astellas US Holding, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 54. Astellas US Holding, Inc. (United States) Revenue: by Geography 2020
• Figure 55. MEDIPOST Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
• Figure 56. MEDIPOST Co., Ltd. (South Korea) Revenue: by Geography 2020
• Figure 57. Anterogen Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
• Figure 58. Anterogen Co., Ltd. (South Korea) Revenue: by Geography 2020
• Figure 59. Pharmicell Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
• Figure 60. Pharmicell Co., Ltd. (South Korea) Revenue: by Geography 2020
• Figure 61. Holostem Terapie Avanzate S.r.l (Italy) Revenue, Net Income and Gross profit
• Figure 62. Holostem Terapie Avanzate S.r.l (Italy) Revenue: by Geography 2020
• Figure 63. JCR Pharmaceuticals Co., Ltd. (Japan) Revenue, Net Income and Gross profit
• Figure 64. JCR Pharmaceuticals Co., Ltd. (Japan) Revenue: by Geography 2020
• Figure 65. NuVasive, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 66. NuVasive, Inc. (United States) Revenue: by Geography 2020
• Figure 67. RTI Surgical, Inc. (United States) Revenue, Net Income and Gross profit
• Figure 68. RTI Surgical, Inc. (United States) Revenue: by Geography 2020
• Figure 69. AlloSource (United States) Revenue, Net Income and Gross profit
• Figure 70. AlloSource (United States) Revenue: by Geography 2020
• Figure 71. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
• Figure 72. Novartis International AG (Switzerland) Revenue: by Geography 2020
• Figure 73. Gilead Sciences (United States) Revenue, Net Income and Gross profit
• Figure 74. Gilead Sciences (United States) Revenue: by Geography 2020
• Figure 75. Global Stem Cell Therapy: by Type USD Million (2021-2026)
• Figure 76. Global Stem Cell Therapy: by Application USD Million (2021-2026)
• Figure 77. Global Stem Cell Therapy: by Cell Source USD Million (2021-2026)
• Figure 78. Global Stem Cell Therapy: by End user USD Million (2021-2026)
• Figure 79. South America Stem Cell Therapy Share (%), by Country
• Figure 80. Asia Pacific Stem Cell Therapy Share (%), by Country
• Figure 81. Europe Stem Cell Therapy Share (%), by Country
• Figure 82. MEA Stem Cell Therapy Share (%), by Country
• Figure 83. North America Stem Cell Therapy Share (%), by Country

• Cellular Dynamics International, Inc. (United States)
• Osiris Therapeutics (United States)
• Vcanbio Cell & Gene Corp. Ltd. (United States)
• Gamida-Cell Ltd. (Israel)
• Golden Meditech Holdings Limited (Hong Kong)
• Celgene Corp. (United States)
• Guanhao Biotech Co. (China)
• Mesoblast Ltd. (Australia)
• Vericel Corp. (United States)
• Stemcell Technologies Inc. (Canada)
• Beike Biotechnology co., Ltd. (China)
• Cytori Therapeutics, Inc. (United States)
• Bioheart Inc. (United States)
• Universal Cells, Inc. (Japan)
• Athersys, Inc. (United States)
• Geron Corp. (United States)
• Pluristem Therapeutics (Israel)
• Fibrocell Science (United States)
• Astellas US Holding, Inc. (United States)
• MEDIPOST Co., Ltd. (South Korea)
• Anterogen Co., Ltd. (South Korea)
• Pharmicell Co., Ltd. (South Korea)
• Holostem Terapie Avanzate S.r.l (Italy)
• JCR Pharmaceuticals Co., Ltd. (Japan)
• NuVasive, Inc. (United States)
• RTI Surgical, Inc. (United States)
• AlloSource (United States)
• Novartis International AG (Switzerland)
• Gilead Sciences (United States)